10,000 UK volunteers are being invited to join a leading phase three COVID-19 vaccine trial - as the number of people signed up to a registry developed by NHS Digital passes 250,000.
The NHS Covid-19 Vaccine Research Registry, hosted on the NHS website, NHS.UK, was launched in July to enable people to consent to be contacted by the NHS to potentially take part in clinical studies – helping to speed up the development of a safe and effective vaccine.
The service was commissioned as part of the UK Government’s Vaccine Taskforce and is being delivered in partnership with the National Institute for Health Research (NIHR).
Today’s Phase 3 study announcement relates to testing the safety and effectiveness of a vaccine developed by US biotechnology company Novavax.
Phase 3 studies involve large groups people across a broad range of ages and backgrounds to give researchers vital insights into the effects of a vaccine on a much larger population than phase 1 and 2 studies.
The Registry will continue to support such studies and NHS Digital and NIHR are also looking at ways to make key information accessible to researchers, building on the COVID-19 vaccine studies volunteer dashboard.
Tom Denwood, Director of Research and Clinical Trials, explains: “Vaccines are one of the safest and most effective ways of keeping people healthy and have the potential to help us mitigate the impacts of COVID-19, both individually and as a society.
“There is some incredible work underway in this space and the Vaccine Research Registry is making a real difference in expanding the number of volunteers. We are proud to support the collective national effort.”
Anyone living in the UK can sign up online to the Registry and give permission to be contacted. You can withdraw this consent at any time and request that your details be removed. The process takes about 5 minutes to complete.
To better understand the effectiveness of vaccine candidates and help find a vaccine that works for as many people as soon as possible, researchers are particularly seeking more volunteers from black, Asian and minority ethnic backgrounds as well as those with underlying health conditions and the over 65s.
Read more about the Novavax phase 3 study announcement